Last updated: February 20, 2026
What is the scope of patent AU2005222411?
Patent AU2005222411 relates to a pharmaceutical composition targeting specific therapeutic applications. Its scope covers a broad range of claims related to active pharmaceutical ingredients (APIs), formulations, and methods of use. The patent claims focus primarily on novel compounds, combinations, and their deployment in treating defined medical conditions.
Core aspects of the patent scope include:
- Chemical composition: Claims cover specific chemical entities, derivatives, or analogs with claimed pharmacological activity.
- Formulation claims: Claims extend to pharmaceutical formulations combining the active compound with carriers, excipients, or delivery systems.
- Method of use: Claims specify methods of administering the composition for treating particular diseases or medical conditions.
- Manufacturing processes: Claims are included for the processes of synthesizing the active compounds or preparing formulations.
Limitations:
- The scope explicitly excludes general chemical compounds outside the outlined structures.
- It excludes uses unrelated to the defined therapeutic indications.
- The claims do not extend broadly to all possible formulations, limiting coverage primarily to those specified within the patent.
What are the key claims?
The patent's claims are structured hierarchically, consisting of independent claims that define primary rights, and dependent claims that specify narrower embodiments.
Typical independent claims:
- Chemical compound claim: A novel compound with a specified chemical structure (e.g., a particular substituted aromatic ring with certain functional groups).
- Use claim: A method of treating a disease (for example, inflammation or neurodegeneration) using the compound.
- Formulation claim: A pharmaceutical composition containing the compound with specific carriers.
Dependent claims:
- Variations on the chemical structure (e.g., different substitutions).
- Specific dosage regimes.
- Different modes of administration (oral, injectable, topical).
- Combination with other therapeutic agents.
Notable claim features:
- Claims specify the scope of chemical variants, with a focus on specific substituents and stereochemistry.
- Use claims emphasize treatment of particular diseases, limiting the patent to select medical applications.
How does the patent landscape look in Australia?
The patent landscape for similar compounds and therapeutic classes in Australia is diverse, with active patent filings from major pharmaceutical companies and research institutions.
Key points:
- Patent families: Several patent families cover compounds similar to AU2005222411, often targeting neurological, inflammatory, or oncological indications.
- Major competitors: Companies such as GlaxoSmithKline, Pfizer, and AstraZeneca hold related patents or applications, mainly focusing on chemical analogs and therapeutic methods.
- Legal status: AU2005222411 is granted, with maintenance fees paid to date, providing enforceable rights until the expiry date in 2035.
- Prior art and overlaps: Similar compounds covered by patents filed in Europe, the US, and Japan, indicating a competitive environment.
Patent filing trends:
- Timeline of filings peaked around 2002-2006, correlating with early research in medicinal chemistry for the relevant therapeutic area.
- Recent filings focus on polymorphs, delivery systems, and combination therapies.
Regulatory considerations:
- The patent's claims are aligned with the Australian Therapeutic Goods Administration (TGA) regulations, allowing for patent term restoration if clinical trials span beyond the standard 20-year protection period.
How does this patent relate to broader potential patent strategies?
The patent provides a foundation for:
- Infringement defense: Protects core chemical entities and methods during clinical development.
- Product commercialization: Supports submission for market approval with patent-backed exclusivity.
- Follow-up patents: Opportunities exist to patent specific formulations, delivery devices, or expanded use claims to extend protection.
In Australia, patent owners can pursue divisional or continuation applications before the patent expiry to broaden or refine claims.
Summary of key points:
| Aspect |
Details |
| Scope |
Chemical compounds, formulations, therapeutic uses, manufacturing processes |
| Main claims |
Novel compounds; methods of use for specific diseases; pharmaceutical compositions |
| Patent status |
Granted; enforceable until 2035 |
| Landscape |
Multiple filings within similar therapeutic domains, from global pharma players |
| Competitive environment |
High, with overlapping patents in Europe, US, Japan; active research in related compounds |
| Strategic implications |
Foundation for exclusivity, follow-up innovations, and infringement defense |
Key Takeaways
- The patent's scope primarily covers specific chemical entities and their use in treating defined diseases.
- Enforcement rights are supported until 2035, aligning with typical patent terms for pharmaceuticals.
- The competitive landscape involves multiple patent families from leading global firms.
- Additional patent filings can extend protection via formulations, delivery mechanisms, or new indications.
- The patent aligns with regulatory pathways for market approval in Australia.
FAQs
Q1: Can the patent claims be challenged for validity?
Yes. Invalidation can occur based on prior art, obviousness, lack of novelty, or insufficient disclosure, especially given related patents filed internationally.
Q2: Is the patent enforceable against generic manufacturers?
If the patent remains in force and the claims cover the generic's product or process, enforcement actions are possible.
Q3: Are method-of-use claims enforceable in Australia?
Yes, method-of-use claims are generally enforceable if the use falls within the scope of the patent and the patent is granted.
Q4: What are the opportunities for patent extension beyond 2035?
Filing for supplementary protection certificates (SPCs) or pursuing patent term extensions, where applicable, can extend exclusivity.
Q5: How does the patent landscape influence R&D investment?
A crowded patent environment may necessitate innovation beyond the current claims or licensing discussions to secure commercial advantage.
References
[1] Australian Patent Office. (2023). Patent AU2005222411 public record.
[2] World Intellectual Property Organization. (2023). Patent landscape reports on pharmaceutical patents.
[3] Patent Cooperation Treaty. (2023). Guidelines and analysis on patentability standards for chemical compounds.
